Showing material events only. Routine administrative filings — bylaw amendments, technical fund updates, procedural FD disclosures — are filtered out so the front page stays signal-dense.
8-K
M&A activity
confidence 75%
filed 2026-09-08
Item 1.01
The Company entered into a stock purchase agreement to acquire 8,693,290 shares of common stock for approximately $31.98 million (8,693,290 × $3.68), representing a material capital deployment and potential change in share structure. While this is a share repurchase rather than a traditional M&A transaction, Item 1.01 disclosure of a "material definitive agreement" combined with the substantial dollar amount and audit committee approval under the related-person transaction policy indicates materiality. The transaction involves a related party (Glenn Sanford's family trust) and was structured to require audit committee oversight, signaling its significance to the registrant.
View raw filing on EDGAR →
8-K
Dilutive issuance
confidence 92%
filed 2026-09-08
Item 3.02
Viper Energy issued 3,815,459 shares of Class B common stock and equivalent LLC membership interests to Diamondback Energy as consideration for acquiring mineral and royalty interests in the "2026 Drop Down" transaction. The issuance was made in reliance on Section 4(a)(2) of the Securities Act, indicating an unregistered private placement. This is a material dilutive equity issuance in connection with an acquisition, affecting shareholder ownership and voting power.
View raw filing on EDGAR →
8-K
Exec appointment
confidence 92%
filed 2026-09-08
Item 5.02
Michele Harradence was appointed as President and Chief Executive Officer effective January 1, 2027, and concurrently appointed to the Board of Directors, succeeding retiring CEO Greg Ebel following a multi-year succession planning process. This represents a material executive leadership transition at the major energy infrastructure company.
View raw filing on EDGAR →
8-K
Operational Other
confidence 75%
filed 2026-09-08
Item 7.01
ArcBest is providing preliminary third-quarter 2026 business trends and operating metrics for its two segments (Asset-Based and Asset-Light), including revenue per day, tonnage, shipments, and operating income guidance. This is a business update disclosing operational performance trends and forward-looking guidance that would inform investors about current business momentum and near-term expectations, but it is not a formal earnings release (which would typically be Item 2.02 with a press release exhibit). The disclosure is material to investors assessing operational performance and trends, but the event type does not fit the specific categories of earnings_release, ma_activity, or other named types—it is a strategic operational disclosure of preliminary results and guidance.
View raw filing on EDGAR →
8-K
M&A activity
confidence 90%
filed 2026-09-08
Item 2.01
On September 1, 2026, the Company completed a material disposition of the Brookfield Center retail property in Greenville, South Carolina for $10,100,000, with concurrent retirement of $4.3 million in mortgage debt. The Company also entered into a material joint venture agreement (Mira Sav Partners LLC) committing $4.0 million for a 42% preferred equity interest and a $13.5 million construction loan guarantee, and reinstated a property purchase agreement with NPH Ventures at a reduced price of $5.40 million.
View raw filing on EDGAR →
8-K
Bankruptcy Filing
confidence 99%
filed 2026-09-08
Item 1.03
Sangamo Therapeutics, Inc. filed a voluntary Chapter 11 bankruptcy petition on June 23, 2026, in the United States Bankruptcy Court for the District of Delaware (Case No. 26-10989). The company is operating as a debtor-in-possession, with its common stock delisted from Nasdaq and trading on the OTCID Basic Market.
View raw filing on EDGAR →
8-K
M&A activity
confidence 95%
filed 2026-09-08
Item 2.01
Sangamo Therapeutics completed a material asset sale to Eli Lilly and Company on September 4, 2026, pursuant to a court-approved Asset Purchase Agreement dated June 22, 2026. The transaction involved the sale of substantially all of the Company's core technology platforms (AAV capsid engineering, zinc finger protein technology, Modular Integrase genome editing, prion disease program, and related IP) for $50 million in cash plus assumption of specified liabilities.
View raw filing on EDGAR →
8-K
Material Litigation
confidence 92%
filed 2026-09-08
Item 8.01
BJ's Wholesale Club disclosed settlement of litigation related to credit card interchange fees in which the Company was a plaintiff, resulting in a one-time pre-tax benefit of approximately $240 million. This is a material litigation settlement that will significantly impact Q3 fiscal 2026 results and is disclosed under Item 8.01 (Other Events), consistent with the material_litigation classification for material settlements.
View raw filing on EDGAR →
6-K
Shareholder vote
confidence 95%
filed 2026-09-08
The 6-K discloses results of an Extraordinary General Meeting held on September 5, 2026, at which shareholders voted on resolutions. The filing reports that 273,457,527 ordinary shares (68.2% of outstanding shares) were present or represented, constituting a quorum, and that "all resolutions presented to the shareholders at its Meeting were duly passed." This is a direct disclosure of shareholder vote results, matching the `shareholder_vote_results` event type. The materiality is high because extraordinary general meetings typically address significant corporate actions (e.g., mergers, capital changes, or governance amendments) that would affect investor assessment.
View raw filing on EDGAR →
8-K
Exec appointment
confidence 93%
filed 2026-09-08
Item 5.02
AdaptHealth appointed Harriss Currie as Chief Financial Officer effective September 9, 2026, with a base salary of $670,000, 100% target bonus, and $818,462 in RSUs. The appointment replaces Jason Clemens' departure as CFO and represents a material change in the company's financial leadership.
View raw filing on EDGAR →
8-K
Exec appointment
confidence 92%
filed 2026-09-08
Item 5.02
Serge Zappone was appointed as President, International and Senior Vice President of Allegion, effective January 1, 2027, succeeding Timothy P. Eckersley and reporting to the CEO.
View raw filing on EDGAR →
8-K
Shareholder vote
confidence 98%
filed 2026-09-08
Item 5.07
Stockholders voted at the Annual Meeting on three matters: re-election of five directors, ratification of Audit Alliance LLP as independent auditor, and approval of the 2026 Stock Incentive Plan. All three proposals passed with overwhelming majorities.
View raw filing on EDGAR →
8-K
Exec Compensation
confidence 95%
filed 2026-09-08
Item 5.02
The filing discloses adjustments to compensation arrangements for two named executives: Ben M. Palmer (President and CEO) and Michael L. Schmit (Vice President, CFO). Specifically, both received base salary increases (Palmer from $637,000 to $750,000; Schmit from $361,000 to $530,000, effective retroactively as of May 16, 2026), and Schmit's target annual cash bonus opportunity was increased to 85% of base salary. These are compensatory arrangements within the scope of Item 5.02(e) and constitute material adjustments to executive pay that would affect investor assessment of the company's cost structure and executive incentives.
View raw filing on EDGAR →
8-K
Exec appointment
confidence 92%
filed 2026-09-08
Item 5.02
Steven Ryder was appointed as Chief Financial Officer of Clearway Energy, Inc., effective October 1, 2026, succeeding Sarah Rubenstein. Samantha Prout was also appointed as SVP Accounting and Controller (principal accounting officer). Sarah Rubenstein transitioned to Head of Transformation Office at the parent company.
View raw filing on EDGAR →
8-K
Exec appointment
confidence 92%
filed 2026-09-08
Item 5.02
Steven Ryder was appointed as Chief Financial Officer of Clearway Energy LLC effective October 1, 2026, succeeding Sarah Rubenstein. Simultaneously, Samantha Prout was appointed as Senior Vice President, Accounting and Controller, effective immediately, also succeeding Rubenstein in her principal accounting officer role. These appointments represent material changes to the company's financial leadership.
View raw filing on EDGAR →
8-K
Dividend Distribution
confidence 98%
filed 2026-09-08
Item 8.01
The board approved declaration of a dividend of $0.4843750 per share on the company's 7.75% Series A Cumulative Perpetual Preferred Stock, with specified record and payment dates. This is a routine but material capital distribution to preferred shareholders that would affect investor assessment of capital allocation and liquidity.
View raw filing on EDGAR →
8-K
Dividend Distribution
confidence 92%
filed 2026-09-08
Item 1.01
United Therapeutics entered into an accelerated share repurchase (ASR) agreement with Citibank to repurchase approximately $477.6 million of common stock, completing its previously announced $2 billion share repurchase program over approximately 2.5 years.
View raw filing on EDGAR →
8-K
Operational Other
confidence 75%
filed 2026-09-08
Item 8.01
Ocugen disclosed material clinical and regulatory progress for its gene therapy pipeline, including initiation of Phase 3 dosing for OCU410 in geographic atrophy following FDA alignment and RMAT designation, and a Data Monitoring Committee recommendation to continue the OCU410ST Phase 2/3 trial for Stargardt disease. The company also posted a corporate presentation detailing clinical trial data, regulatory milestones, and market potential for three programs (OCU400, OCU410ST, and OCU410).
View raw filing on EDGAR →
8-K
M&A activity
confidence 98%
filed 2026-09-08
Item 1.01
IPG Photonics entered into a Share Purchase Agreement on September 8, 2026, to acquire 100% of Lumibird Medical from Lumibird S.A. for €300 million in cash plus up to €50 million in contingent earn-out consideration. This is a material acquisition of a wholly-owned subsidiary, disclosed under Item 1.01 (Entry in a Material Definitive Agreement), with closing expected in Q4 2026. The transaction size and strategic nature make it material to investors.
View raw filing on EDGAR →
8-K
M&A activity
confidence 99%
filed 2026-09-08
Item 1.01
WaFd, Inc. entered into a definitive Agreement and Plan of Merger with EverBank Financial Corp on September 6, 2026, whereby EverBank will merge into WaFd with WaFd as the surviving corporation. The transaction is valued at approximately $3.9 billion with EverBank shareholders receiving approximately 59.2% ownership of the pro forma combined company, subject to regulatory and shareholder approval with expected closing in early 2027.
View raw filing on EDGAR →
8-K
Exec Compensation
confidence 85%
filed 2026-09-08
Item 5.02
WaFd disclosed new employment agreements and compensatory arrangements for CEO Brent J. Beardall and COO Kim E. Robison in connection with the merger, including specified base salaries, bonus structures, severance provisions (2x base plus target bonus over 24 months), and lump-sum continuity payments of $5,025,000 and $1,930,000 respectively.
View raw filing on EDGAR →
8-K
Exec appointment
confidence 95%
filed 2026-09-08
Item 5.02
The filing discloses the appointment of Brent Moen as Chief Financial Officer effective September 11, 2026, with detailed compensation arrangements including a $475,000 base salary, bonus opportunity, and $500,000 long-term incentive award. While the section also mentions Matthew McDonnell's transition from CFO to Head of Australia, the principal disclosed action centers on the appointment of a new CFO, a material executive position. This is a clear exec_appointment event.
View raw filing on EDGAR →
6-K
Dividend Distribution
confidence 95%
filed 2026-09-08
EX-99.1
The exhibit announces that Hafnia Limited's shares will trade ex-dividend on the Oslo Stock Exchange on 7 September 2026 and the NYSE on 8 September 2026, with a dividend of USD 0.5003 per share for the second quarter 2026. This is a routine but material dividend distribution announcement disclosing the ex-dividend date and per-share amount to shareholders.
View raw filing on EDGAR →
8-K
Dilutive issuance
confidence 93%
filed 2026-09-08
Item 1.01
PDS Biotechnology entered into a Securities Purchase Agreement for an unregistered private placement (PIPE) raising up to $22.55 million through the issuance of common stock, pre-funded warrants, and common warrants to accredited investors led by Nant Capital. The Initial Closing involves approximately $11.55 million in gross proceeds with ~20.9 million common shares and ~20 million pre-funded warrants, with a contingent Milestone Closing of up to $11 million more, subject to Section 4(a)(2) and Regulation D exemptions.
View raw filing on EDGAR →
8-K
Operational Other
confidence 75%
filed 2026-09-08
Item 7.01
The disclosure announces positive Phase 2 clinical trial results for mosliciguat in pulmonary hypertension associated with interstitial lung disease, including achievement of primary and secondary endpoints with statistically significant improvements in pulmonary vascular resistance (-56.3%), six-minute walk distance (+35.2m), and NT-proBNP reduction (-53.2%). The filing also announces initiation of a Phase 3 trial (PHrontier). This is a material clinical development milestone for a biopharmaceutical company's pipeline asset, representing significant progress toward potential regulatory approval and commercialization, though it does not fit neatly into the specific financial, governance, or legal event categories.
View raw filing on EDGAR →
8-K
Exec appointment
confidence 95%
filed 2026-09-08
Item 5.02
Shutterstock appointed three new directors—Timothy Adams, Matthew Salzberg, and Michael Thompson—to its Board of Directors, effective September 8, 2026, as Class II and Class III directors based on the Nominating Committee's recommendation. The appointees bring extensive financial, operational, investment, and technology expertise to strengthen the Board's governance.
View raw filing on EDGAR →
8-K
M&A activity
confidence 95%
filed 2026-09-08
Item 1.02
Neighborhood Intelligence, Inc. terminated the Agreement and Plan of Merger dated July 23, 2026, with F9 Investments, LLC for the acquisition of F9 Brands, Inc. The termination of this previously announced material acquisition affects the company's capital allocation and growth strategy.
View raw filing on EDGAR →
8-K
Shareholder vote
confidence 98%
filed 2026-09-08
Item 5.07
This Item 5.07 discloses the results of a special stockholder meeting held on September 8, 2026, where AtaiBeckley stockholders voted to approve the Merger Agreement with Eli Lilly and Company. The Merger Proposal was approved with 237,762,253 votes in favor (97.8% of votes cast), representing a material M&A transaction. The filing explicitly presents voting tallies for each proposal and confirms the merger is expected to close on September 11, 2026.
View raw filing on EDGAR →
8-K
Operational Other
confidence 75%
filed 2026-09-08
Item 8.01
Brookfield announced selection by the Nuclear Liabilities Fund to manage a multi-decade investment mandate with an initial $1 billion commitment across Brookfield's infrastructure, energy, private equity, real estate, and credit strategies. This is a material business development—a significant new client relationship and investment mandate—but does not fit neatly into the specific event categories (not M&A, not a debt/equity issuance, not a restructuring). It is clearly operational/strategic in nature, representing a major institutional client win that would affect investor assessment of the registrant's business prospects and AUM growth.
View raw filing on EDGAR →
6-K
Operational Other
confidence 75%
filed 2026-09-08
Novartis announced that its Phase III HARBOR study of del-desiran for myotonic dystrophy type 1 (DM1) failed to meet its primary endpoint of video hand opening time (vHOT), though secondary endpoints showed some clinical activity. This is a material clinical trial failure for an investigational therapy in Novartis's neuromuscular pipeline acquired through Avidity Biosciences. While the company maintains its 5-6% sales CAGR guidance and continues advancing other AOC therapies (del-zota and del-brax), the HARBOR failure represents a significant setback in a high-unmet-need indication and would affect investor assessment of the pipeline's value and development strategy.
View raw filing on EDGAR →
6-K
Operational Other
confidence 75%
filed 2026-09-08
EX-99.1
This press release announces positive results of a Preliminary Economic Assessment (PEA) for the Franklin Project, a greenfield lithium extraction facility in East Texas. The disclosure presents material operational and strategic milestones—a $5.0 billion after-tax NPV, 24% IRR, 70,000 tpa production capacity, and upgraded mineral resources—that would affect a reasonable investor's assessment of the company's project pipeline and value creation potential. While not a discrete M&A transaction, earnings release, or governance event, this represents a significant operational/strategic development in project advancement that warrants classification as a material operational event.
View raw filing on EDGAR →
6-K
Operational Other
confidence 75%
filed 2026-09-08
EX-99.1
This press release announces publication of peer-reviewed pilot study results showing 83.3% response rate and 50% remission rate for BrainsWay's Deep TMS technology in patients with depression and early-stage Alzheimer's disease, with measurable neurophysiological changes. While the study is preliminary and not FDA-cleared for Alzheimer's indication, the positive clinical findings and peer-reviewed publication represent a material operational/scientific milestone that would affect investor assessment of the company's product pipeline and clinical evidence base. This is not an earnings release (no financial results), but rather a clinical/product development milestone that is material to the company's strategic positioning.
View raw filing on EDGAR →
6-K
Delisting risk
confidence 92%
filed 2026-09-08
EX-99.1
The press release announces that Eupraxia's common shares "have commenced trading on the Nasdaq Global Select Market," representing a transfer from the Nasdaq Capital Market to Nasdaq's highest market tier. While this is technically an upgrade rather than a delisting risk, the delisting_risk category encompasses "transfer of listing" per the taxonomy. The move to the Global Select Market—Nasdaq's most stringent tier—is material to investors as it signals improved financial and liquidity standing and enhanced corporate governance compliance, affecting the registrant's market positioning and investor perception.
View raw filing on EDGAR →
8-K
Exec appointment
confidence 95%
filed 2026-09-08
Item 5.02
Northern Technologies International Corp announced a planned executive succession effective September 4, 2026, with Gautam Ramdas appointed as President and Chief Executive Officer and elected to the Board, Brian Haglund appointed as Chief Operating Officer, G. Patrick Lynch transitioning from CEO to Chairman, and Richard Nigon appointed as lead independent director. The appointments include compensation arrangements for the new executives.
View raw filing on EDGAR →
8-K
Dividend Distribution
confidence 85%
filed 2026-09-08
Item 8.01
The filing's primary disclosure is the declaration of a special cash dividend of $0.75 per share plus a regular quarterly dividend of $0.25 per share, payable September 25, 2026. While the section also mentions Kaitlyn O'Neil's promotion to Chief Financial Officer, the dividend announcement is the lead event in both the Item 8.01 disclosure and the press release, and represents a material capital distribution to shareholders. The executive appointment is secondary and does not rise to the level of a named executive departure or appointment that would typically trigger Item 5.02.
View raw filing on EDGAR →
6-K
Exec departure
confidence 95%
filed 2026-09-08
Eran Havshush, a member of the Board since July 2024, resigned as a director effective September 1, 2026, following adoption of a revised Remuneration Policy that prohibits non-executive directors from providing services other than board service. While the resignation was amicable and not due to disagreement, it constitutes a material departure of a director that would affect a reasonable investor's assessment of board composition and governance.
View raw filing on EDGAR →
6-K
Shareholder vote
confidence 95%
filed 2026-09-08
The 6-K furnishes the resolutions adopted at Gilat's Annual General Meeting of Shareholders held on September 8, 2026. The document explicitly states "all proposed resolutions were adopted by the required majority" and lists nine discrete shareholder votes, including board composition, director re-elections, share capital authorization, compensation policy amendments, executive equity grants, and auditor reappointment. This is a classic shareholder_vote_results disclosure under Item 5.07 equivalent, material because it confirms approval of executive compensation arrangements and board composition.
View raw filing on EDGAR →
6-K
Earnings release
confidence 95%
filed 2026-09-08
EX-99.1
This exhibit is a press release announcing Kenon Holdings' Q2 2026 financial results, including consolidated revenue of $379 million, profit of $15 million, and Adjusted EBITDA of $131 million for the period ended June 30, 2026. The document explicitly states "Kenon Holdings Reports Q2 2026 Results and Additional Updates" and provides detailed financial performance metrics, revenue breakdowns by geography, and cost analysis—all hallmarks of a quarterly earnings release. Material updates on the Hadera Expansion Project, Series E bond issuance, and Peru arbitration award receipt are disclosed alongside the results.
View raw filing on EDGAR →
6-K
Governance Other
confidence 88%
filed 2026-09-08
EX-99.2
YY Group Holding Limited rebranded to YYForce Inc. with a concurrent Nasdaq ticker symbol change from YYGH to YFOR, effective September 2, 2026, reflecting a strategic evolution in the company's positioning around AI, automation, and workforce management.
View raw filing on EDGAR →
6-K
Exec Compensation
confidence 95%
filed 2026-09-08
EX-99
The disclosure announces a grant by the Governance, Nomination and Remuneration Committee of approximately 5.86 million equity stock options and 1.67 million restricted stock units to employees under multiple SEBI-regulated share-based compensation schemes (ESOS-063, ESOS-064, RSU-018, RSU-019, RSU-020). This is a material compensatory arrangement affecting employee equity incentives and potential share dilution, requiring disclosure under Item 5.02(e) equivalent standards for foreign private issuers.
View raw filing on EDGAR →
6-K
Operational Other
confidence 75%
filed 2026-09-08
EX-99.1
This exhibit is an investor presentation disclosing AIR Global PLC's H1'2026 financial performance, strategic positioning, and forward guidance. The presentation covers resilient revenue growth (3.7% despite Strait of Hormuz disruption), Adjusted EBITDA performance ($71.7m, flat YoY), and medium-term outlook including low-single-digit FSM volume growth and high-single-digit EBITDA growth. While the document contains financial metrics and guidance, it is a strategic business presentation rather than a formal periodic financial report or earnings release press statement. The disclosure is material as it provides investors with updated operational performance, market positioning, and forward-looking guidance that would affect investment decisions.
View raw filing on EDGAR →
8-K
Dilutive issuance
confidence 94%
filed 2026-09-08
Item 1.01
Fold Holdings entered into a Common Stock Purchase Agreement with Roth Principal Investments granting the right to sell up to $25,000,000 of newly issued common stock over 36 months at a 3.0–5.0% discount to VWAP, with an Exchange Cap of 10,942,804 shares (19.99% of outstanding). The Company also completed an unregistered sale of common stock to Roth Principal Investments under Section 4(a)(2) and Regulation D Rule 506(b), representing a material dilutive equity issuance.
View raw filing on EDGAR →
6-K
Earnings release
confidence 92%
filed 2026-09-08
EX-99.1
This is a press release announcing positive topline results from the CHAPTER-3 pivotal Phase 3 clinical trial of deucrictibant XR for HAE prophylaxis. The disclosure reports that the primary endpoint was met with 83% attack rate reduction versus placebo (p<0.0001), all secondary efficacy endpoints were met with statistical significance, and the drug demonstrated a well-tolerated safety profile. While technically a clinical trial result rather than financial earnings, this constitutes a material clinical milestone disclosure that would significantly affect investor assessment of the company's pipeline value and regulatory prospects, warranting classification as an earnings_release analog for a clinical-stage biotech company.
View raw filing on EDGAR →
6-K
M&A activity
confidence 92%
filed 2026-09-08
Vista announced the completion of a material acquisition consummated on May 7, 2026, acquiring 25.1% working interest in Bandurria Sur and 35.0% working interest in Bajo del Toro blocks in Argentina, adding 66.8 MMboe of proved reserves to the company's portfolio. The transaction involved acquisition of 100% of BSP (holder of 30% Bandurria Sur interest) from Equinor and a 50% Bajo del Toro interest, with back-to-back sales to YPF, representing a significant expansion of Vista's reserve base (from 588.1 to 654.9 MMboe pro forma).
View raw filing on EDGAR →
6-K
Exec appointment
confidence 95%
filed 2026-09-08
EX-99.1
The exhibit announces the appointment of Martin Dewhurst to NovaBridge's Board of Directors as an independent director and member of the Audit and Compensation Committees, effective immediately. This is a clear governance event involving the appointment of a named executive/director with substantial healthcare and board experience. The disclosure also notes the concurrent departure of independent director Liu Xin, but the principal action disclosed is Dewhurst's appointment to the board and committees.
View raw filing on EDGAR →
6-K
Shareholder vote
confidence 95%
filed 2026-09-08
The 6-K discloses the voting results of NovaBridge Biosciences' 2026 Annual General Meeting held on September 8, 2026, specifically the shareholder approval of an ordinary resolution to remove Ms. Xin Liu from her position as a director with immediate effect. The vote tally (107,925,508 for, 13,313,327 against, 55,453 abstain) and quorum confirmation (44.8% of outstanding shares) are clearly presented, matching the `shareholder_vote_results` taxonomy entry. This is material as it represents a change in board composition.
View raw filing on EDGAR →
8-K
Operational Other
confidence 75%
filed 2026-09-08
Item 8.01
Monte Rosa announced that its collaborator Novartis has initiated a Phase 2 clinical study for MRT-6160 (DDY391) in Sjögren's disease, triggering a $50 million milestone payment and eligibility for up to $2.1 billion in additional development, regulatory, and sales milestones under their global exclusive license agreement. This represents a material operational and strategic milestone validating the company's technology platform and demonstrating significant progress in its partnered pipeline.
View raw filing on EDGAR →
8-K
Exec appointment
confidence 95%
filed 2026-09-08
Item 5.02
The filing discloses the appointment of Jennifer Fulk as Chief Financial Officer, principal financial officer, and principal accounting officer of Kura Oncology, effective September 8, 2026. While the disclosure includes compensatory details (base salary of $550,000, bonus eligibility, equity awards of 450,000 options and 173,438 PSUs, and severance provisions), the principal action is the appointment of a named executive officer to a key financial leadership role. This is material to investors as CFO changes affect financial oversight and governance.
View raw filing on EDGAR →
8-K
Earnings release
confidence 98%
filed 2026-09-08
Item 2.02
ABM Industries issued a press release on September 8, 2026, announcing financial results for the fiscal third quarter ended July 31, 2026, including quarterly revenue of $2.3 billion (up 4.2%), net income of $49.7 million (up 19%), adjusted EPS of $1.04 (up 19%), and adjusted EBITDA of $139.6 million (up 11%), along with raised full-year guidance.
View raw filing on EDGAR →
8-K
Dividend Distribution
confidence 95%
filed 2026-09-08
Item 8.01
The Board of Directors declared a quarterly dividend of $0.29 per share, payable November 2, 2026 to stockholders of record on October 1, 2026.
View raw filing on EDGAR →